Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 8/2012

01-08-2012 | Original article

FOXP3+ cell density in lymphoid follicles from histologically normal mucosa is a strong prognostic factor in early stage colon cancer

Authors: Paul Salama, Colin Stewart, Cynthia Forrest, Cameron Platell, Barry Iacopetta

Published in: Cancer Immunology, Immunotherapy | Issue 8/2012

Login to get access

Abstract

There are few clearly established prognostic factors available to guide the use of adjuvant chemotherapy in early stage colon cancer patients. Some of the most promising candidates include the invasion of extramural blood vessels by tumour cells and the densities of FOXP3+ T regulatory cells (Tregs) in tumour and adjacent normal colonic mucosal tissue. The aim of our study was to evaluate the prognostic significance of these markers in AJCC stage II colon cancer, with particular reference to lymphoid follicles in the mucosa. Histopathological review for the presence of vascular and serosal invasion was conducted on a series of 165 stage II colon cancers treated by surgery alone. Immunohistochemical staining for FOXP3 was performed on tumour tissue and histologically normal colonic mucosa from the surgical margin. Image analysis software was used to evaluate the density of FOXP3+ cells in the tumour core, invading margin and lymphoid follicles from the colonic mucosa. For survival analysis, cases were classified into high- or low-density of FOXP3+ cells according to the median value. The mean density of FOXP3+ Tregs in lymphoid follicles was twofold and fivefold higher than in the invading margin and tumour core, respectively. Multivariate analysis identified extramural vascular invasion (HR, 2.47; 95% CI: 1.00–6.07; P = 0.05) and high FOXP3+ cell density in lymphoid follicles (HR, 4.22; 95% CI: 1.49–11.91; P = 0.007) as independent factors for worse survival, whereas a high frequency of lymphoid follicles in histologically normal colonic mucosa was associated with better survival (HR, 0.31; 95% CI: 0.12–0.79; P = 0.014). Our data suggest that host factors related to the immune system have major prognostic significance in early stage colon cancer. The density of FOXP3+ cells within lymphoid follicles and the frequency of these structures in normal colonic mucosa represent novel and independent prognostic factors.
Literature
1.
Sobin LH, Wittekind C (1997) International union against cancer TNM classification of malignant tumours, 5th edn. Wiley, Hoboken
2.
3.
Williams GT, Quirke P, Shepherd NA (2007) Standards and datasets for reporting cancers. Dataset for colorectal cancer, 2nd edn. Royal College of Pathologists, London
4.
Petersen VC, Baxter KJ, Love SB, Shepherd NA (2002) Identification of objective pathological prognostic determinants and models of prognosis in Dukes’ B colon cancer. Gut 51:65–69PubMedCrossRef
5.
Morris M, Platell C, de Boer B, McCaul K, Iacopetta B (2006) Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 93:866–871PubMedCrossRef
6.
Stewart CJ, Morris M, de Boer B, Iacopetta B (2007) Identification of serosal invasion and extramural venous invasion on review of Dukes’ stage B colonic carcinomas and correlation with survival. Histopathology 51:372–378PubMedCrossRef
7.
Desolneux G, Burtin P, Lermite E, Bergamaschi R, Hamy A, Arnaud JP (2010) Prognostic factors in node-negative colorectal cancer: a retrospective study from a prospective database. Int J Colorectal Dis 25:829–834PubMedCrossRef
8.
Courtney ED, West NJ, Kaur C, Ho J, Kalber B, Hagger R, Finlayson C, Leicester RJ (2009) Extramural vascular invasion is an adverse prognostic indicator of survival in patients with colorectal cancer. Colorectal Dis 11:150–156PubMedCrossRef
9.
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491–3494PubMed
10.
Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182:318–324PubMedCrossRef
11.
Prall F, Dührkop T, Weirich V, Ostwald C, Lenz P, Nizze H, Barten M (2004) Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 35:808–816PubMedCrossRef
12.
Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, Ohuchi A, Ohuchi K, Shiiba K, Kurokawa Y, Satomi S (2004) Intraepithelial CD8+ T-cell-count become a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 91:1711–1717PubMed
13.
Ohtani H (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7:4PubMed
14.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRef
15.
Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666PubMedCrossRef
16.
Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, Mantovani A, Roncalli M, Malesci A (2009) CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10:877–884PubMedCrossRef
17.
Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500PubMedCrossRef
18.
Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186–192PubMedCrossRef
19.
Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L, Tornillo L (2010) High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 126:2635–2643PubMed
20.
Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, Tassone P, Francini G, Tagliaferri P (2010) Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 33:435–441PubMedCrossRef
21.
Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S (2010) Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222:350–366PubMedCrossRef
22.
Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D (2006) In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 4:52PubMedCrossRef
23.
Ladoire S, Martin F, Ghiringhelli F (2011) Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60:909–918PubMedCrossRef
24.
Betge J, Pollheimer MJ, Lindtner RA, Kornprat P, Schlemmer A, Rehak P, Vieth M, Hoefler G, Langner C (2011) Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer. doi:10.​1002/​cncr.​26310. [Epub ahead of print]
25.
Lee WS, Park S, Lee WY, Yun SH, Chun HK (2010) Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 116:5188–5199PubMedCrossRef
26.
Langman JM, Rowland R (1986) The number and distribution of lymphoid follicles in the human large intestine. J Anat 149:189–194PubMed
27.
Nascimbeni R, Di Fabio F, Di Betta E, Mariani P, Fisogni S, Villanacci V (2005) Morphology of colorectal lymphoid aggregates in cancer, diverticular and inflammatory bowel diseases. Mod Pathol 18:681–685PubMedCrossRef
28.
Sipos F, Muzes G (2011) Isolated lymphoid follicles in colon: switch points between inflammation and colorectal cancer? World J Gastroenterol 17:1666–1673PubMedCrossRef
29.
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S, Fridman WH, Cadranel J (2008) Long-term survival for patients with non-small-cell lung cancer with intra- tumoural lymphoid structures. J Clin Oncol 26:4410–4417PubMedCrossRef
30.
Fu KI, Sano Y, Kato S, Fujii T, Koba I, Yoshino T, Ochiai A, Yoshida S, Fujimori T (2005) Incidence and localization of lymphoid follicles in early colorectal neoplasms. World J Gastroenterol 11:6863–6866PubMed
31.
Lim HW, Hillsamer P, Banham AH, Kim CH (2005) Direct suppression of B cells by CD4 +CD25+ regulatory T cells. J Immunol 175:4180–4183PubMed
Metadata
Title
FOXP3+ cell density in lymphoid follicles from histologically normal mucosa is a strong prognostic factor in early stage colon cancer
Authors
Paul Salama
Colin Stewart
Cynthia Forrest
Cameron Platell
Barry Iacopetta
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 8/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1191-3

Other articles of this Issue 8/2012

Cancer Immunology, Immunotherapy 8/2012 Go to the issue

Focussed Research Review

The expression, function, and clinical relevance of B7 family members in cancer

Meeting Report

Eleventh international conference on progress in vaccination against cancer (PIVAC-11), 10–13 October 2011, Copenhagen, Denmark

Original article

In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy

Focussed Research Review

TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

Focussed Research Review

Harnessing human plasmacytoid dendritic cells as professional APCs

Original article

Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits